Humira Biosimilar List: Approved Options

Complete Humira Biosimilar List

Humira (adalimumab) was the world’s top-selling drug for over a decade, with U.S. sales peaking at $21.2 billion in 2022. The expiration of AbbVie’s patent protections opened the door for biosimilar competition, and the Humira biosimilar list has grown rapidly since the first U.S. launch in January 2023. As of 2026, the FDA has approved roughly ten adalimumab biosimilars, and several are actively competing for market share in pharmacies and health-plan formularies.

This Humira biosimilar list is a comprehensive reference for FDA-approved adalimumab biosimilars, including approval years, interchangeability status, concentration and formulation notes, manufacturers, and pricing context. Because approvals, interchangeability designations, and formulations change over time, treat this as a well-researched snapshot and verify any specific product’s current status in the FDA Purple Book before making decisions. Whether you are a patient evaluating a switch, a caregiver researching options, or simply tracking the landscape, this guide gives you a solid starting point — and any change to your therapy should be made with your prescriber.

Understanding the List: Key Terms

Before reviewing the individual products, a few key terms will help you compare them effectively.

Biosimilar: A biological product that is highly similar to the reference biologic (Humira) with no clinically meaningful differences in safety, purity, or potency. All products on this list meet this standard.

Interchangeable: An additional FDA designation — separate from being a biosimilar — indicating a product met further requirements that can allow substitution at the pharmacy level (where state law permits) without the prescriber writing a new prescription, similar to how generic drugs are substituted. Not all biosimilars carry this designation. Importantly, FDA policy in this area has been evolving: in 2024–2025 the agency signaled, through draft guidance, that it may no longer require separate switching studies for interchangeability, which could blur the practical distinction over time. Always confirm a product’s current interchangeability status in the FDA Purple Book, and remember that substitution rules also depend on your state.

Concentration (high vs. low): Adalimumab is sold in low-concentration (50 mg/mL) and high-concentration (100 mg/mL) formulations. High-concentration versions deliver the same dose in a smaller injection volume, which many patients find more comfortable. Products differ in which concentrations they offer.

Citrate-free: A formulation that removes citrate, a buffering agent that can cause stinging during injection. Many patients prefer citrate-free versions for improved injection comfort. Humira’s current pen formulation is citrate-free and high-concentration, and most biosimilar manufacturers offer citrate-free options.

WAC (Wholesale Acquisition Cost): The manufacturer’s list price to wholesalers. This is not what patients pay at the pharmacy, but it serves as a benchmark for comparing relative pricing between products.

FDA-Approved Adalimumab Biosimilars

The following products make up the current Humira biosimilar list, presented in order of FDA approval date. Interchangeability notes are provided where a designation has been reported, but should be re-checked in the Purple Book, as noted above.

1. Amjevita (adalimumab-atto) — Amgen

• FDA approval: September 2016
• U.S. launch: January 2023
• Interchangeable: Verify current status in the FDA Purple Book
• Concentration / citrate-free: Available in multiple presentations; citrate-free options offered
• Notes: The first Humira biosimilar to launch in the U.S. Amgen offers a copay assistance program for eligible commercially insured patients.

2. Cyltezo (adalimumab-adbm) — Boehringer Ingelheim

• FDA approval: August 2017
• U.S. launch: July 2023
• Interchangeable: Yes — the first adalimumab biosimilar to receive interchangeable designation (October 2021)
• Concentration / citrate-free: Citrate-free
• Notes: Boehringer Ingelheim has positioned Cyltezo with flexible pricing to attract formulary placement.

3. Hyrimoz (adalimumab-adaz) — Sandoz

• FDA approval: October 2018
• U.S. launch: July 2023
• Interchangeable: Interchangeable designation reported (2024) — verify in the Purple Book
• Concentration / citrate-free: High-concentration (100 mg/mL) citrate-free version available; other presentations offered
• Notes: Sandoz is one of the world’s largest biosimilar companies, and Hyrimoz has extensive post-market use in Europe since 2018. A co-branded/private-label version has featured in some U.S. formulary strategies.

4. Hadlima (adalimumab-bwwd) — Samsung Bioepis / Organon

• FDA approval: July 2019
• U.S. launch: July 2023
• Interchangeable: Interchangeable designation reported — verify in the Purple Book
• Concentration / citrate-free: Available in both high- and low-concentration presentations; citrate-free options
• Notes: Samsung Bioepis (commercialized in the U.S. with Organon) has a growing biosimilar portfolio across multiple therapeutic areas.

5. Abrilada (adalimumab-afzb) — Pfizer

• FDA approval: November 2019
• U.S. launch: 2023
• Interchangeable: Interchangeable designation reported (2023) — verify in the Purple Book
• Concentration / citrate-free: Citrate-free; high-concentration presentation available
• Notes: Backed by Pfizer’s extensive distribution network, with patient support programs.

6. Hulio (adalimumab-fkjp) — Fujifilm Kyowa Kirin / Biocon-Viatris (U.S.)

• FDA approval: July 2020
• U.S. launch: 2023
• Interchangeable: Biosimilar (interchangeable designation not established as of this writing) — verify in the Purple Book
• Concentration / citrate-free: Verify current presentations with the manufacturer
• Notes: Commercialization has involved Viatris/Biocon Biologics; the focus has been on payer contracts and formulary access.

7. Yusimry (adalimumab-aqvh) — Coherus BioSciences

• FDA approval: December 2021
• U.S. launch: 2023
• Interchangeable: Biosimilar (interchangeable designation not established as of this writing) — verify in the Purple Book
• Concentration / citrate-free: Citrate-free
• Notes: Coherus positioned Yusimry as a value option and it has appeared at notably low cash prices through certain low-cost pharmacy channels.

8. Idacio (adalimumab-aacf) — Fresenius Kabi

• FDA approval: December 2022
• U.S. launch: 2023
• Interchangeable: Biosimilar (interchangeable designation not established as of this writing) — verify in the Purple Book
• Concentration / citrate-free: Citrate-free; low-concentration (50 mg/mL) presentation
• Notes: Fresenius Kabi has extensive European experience with Idacio, marketed in the EU since 2019.

9. Yuflyma (adalimumab-aaty) — Celltrion

• FDA approval: May 2023
• U.S. launch: July 2023
• Interchangeable: Interchangeable designation reported (2024) — verify in the Purple Book
• Concentration / citrate-free: High-concentration (100 mg/mL) and citrate-free — a key selling point
• Notes: Celltrion markets Yuflyma directly in the U.S. Its high-concentration, citrate-free formulation matches the current Humira pen format.

10. Simlandi (adalimumab-ryvk) — Alvotech / Teva

• FDA approval: February 2024
• U.S. launch: 2024
• Interchangeable: Yes — approved with interchangeable designation
• Concentration / citrate-free: High-concentration (100 mg/mL) and citrate-free
• Notes: Developed by Alvotech and commercialized in the U.S. by Teva. One of the newer entrants launched as an interchangeable, high-concentration, citrate-free option.

Additional adalimumab biosimilars have been developed and may be approved or launched over time, so the list continues to evolve. The FDA Purple Book is the authoritative place to confirm the full current roster and each product’s designations.

A Note on Interchangeability (Read Before You Assume)

Interchangeability is one of the most misunderstood parts of the biosimilar landscape. Being “interchangeable” is a distinct FDA designation layered on top of being a biosimilar; historically it required additional switching data and could permit pharmacy-level substitution where state law allows. Several adalimumab products (including Cyltezo, and later others such as Hyrimoz, Hadlima, Abrilada, Yuflyma, and Simlandi) have been reported to hold this designation. However, because the FDA has moved toward treating biosimilars and interchangeables as equally safe and effective — and has signaled it may stop requiring separate switching studies — the day-to-day importance of the label is shifting. The practical takeaways: (1) do not assume a product is or isn’t interchangeable from memory; check the FDA Purple Book; (2) substitution also depends on your state’s pharmacy laws; and (3) any switch should be coordinated with your prescriber and pharmacy regardless of designation.

How to Read Your Insurance Formulary

A long Humira biosimilar list does not help if you do not know which product your plan covers. Here is how to find out.

Check your plan’s formulary: Your insurer publishes a formulary (drug list) on its website or member portal. Search for “adalimumab” to see which products are covered and at what tier.

Look for preferred products: Plans often designate one or two biosimilars as “preferred,” placing them on a lower copay tier. Using the preferred product usually saves the most money. Some plans have removed brand-name Humira from their formulary entirely, making a biosimilar the only covered option.

Ask about prior authorization: Some plans require prior authorization before covering any adalimumab product, brand or biosimilar. Your prescriber’s office typically handles this process.

The 2024 Formulary Shift

For much of 2023, biosimilar uptake was slow because rebate-driven contracting kept brand Humira on many formularies. That changed in 2024, when several large pharmacy benefit managers (PBMs) restructured their formularies to favor biosimilars — and some removed brand-name Humira from major commercial formularies altogether, in certain cases steering patients toward a specific (sometimes private-label or co-branded) biosimilar. This is why many patients received letters about switching products even when their condition was stable. If you were switched, the change was almost always a formulary/coverage decision by your plan, not a clinical judgment about your care — but you should still confirm the details with your prescriber and pharmacy, and report any change in how you feel.

Pricing Comparison

Direct price comparisons are difficult because net prices (after rebates and discounts) differ from list prices. Still, here is a general framework based on WAC data:

• Humira (brand): WAC historically around $6,900 per month
• Biosimilars at a modest discount (about 5–10%): roughly $6,200 to $6,550 per month WAC
• Biosimilars at a deep discount (about 50–85%): roughly $1,000 to $3,450 per month WAC

The wide range reflects different manufacturer strategies. Some price close to Humira to capture rebate-driven formulary placement, while others price aggressively low to win market share and cash-pay patients. Your actual cost depends on your plan’s negotiated rate, your copay or coinsurance, and whether you use a manufacturer savings card. For uninsured patients, the deeply discounted biosimilars — and low-cost cash pharmacy channels — can offer the most direct savings.

Patient Assistance and the myAbbVie Assist Change

Manufacturer patient assistance programs can reduce or eliminate costs for eligible patients. AbbVie’s myAbbVie Assist program has historically helped qualifying uninsured or underinsured patients access brand Humira. Reports indicate this assistance for Humira is being wound down — with new enrollments for Humira expected to stop around mid-2026 — as the market shifts to biosimilars. Because program terms and dates can change, verify current eligibility and deadlines directly with the program before relying on it, and ask your prescriber and pharmacy about biosimilar manufacturer assistance programs as alternatives. For more strategies, see the resources linked at the end of this guide.

Conditions Treated by Humira Biosimilars

FDA-approved adalimumab biosimilars are generally approved for the same indications as Humira, which include:

• Rheumatoid arthritis
• Juvenile idiopathic arthritis (ages 2 and older)
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn’s disease (adults and pediatric patients ages 6 and older)
• Ulcerative colitis
• Plaque psoriasis
• Hidradenitis suppurativa
• Uveitis

Some biosimilars are approved for these indications through a regulatory process called “extrapolation,” which lets the FDA extend approval to conditions not directly studied in the biosimilar’s own clinical trial, based on the totality of evidence. A given product’s exact approved indications can vary slightly, so confirm the labeling for the specific product you are prescribed.

Frequently Asked Questions

Which Humira biosimilar is the cheapest?

Based on WAC and cash-pay channels, some deeply discounted products (for example Yusimry through certain low-cost pharmacies, and aggressively contracted tiers of products like Hyrimoz or Cyltezo) offer the largest discounts — in some cases well over 80% below Humira’s list price. But your actual cost depends on your insurance formulary and negotiated rates. For more on how biosimilars save you money, see our companion guide, and compare with our biosimilar overview.

Are all Humira biosimilars interchangeable?

No. Interchangeability is a separate designation, and not every product carries it. Several products have been reported as interchangeable (Cyltezo was first, in 2021, and Simlandi launched as interchangeable), while others are approved as biosimilars only. Because FDA policy and individual designations have been changing, verify any product’s current status in the FDA Purple Book, and note that substitution also depends on your state’s law.

Can I switch between different Humira biosimilars?

Clinically, switching between adalimumab products (including between biosimilars) has not been shown to increase risk in available studies. However, your insurance plan may prefer a specific product, and any switch should be discussed with your doctor and coordinated with your pharmacy and insurer.

Do Humira biosimilars have the same side effects?

Yes. The FDA requires biosimilars to have no clinically meaningful differences in safety compared with the reference product. Per MedlinePlus, adalimumab is a TNF inhibitor, and all products in this class carry serious warnings, including an increased risk of serious infections (which may require hospitalization) and of certain cancers. Discuss your personal risks with your prescriber.

Will more Humira biosimilars be approved?

Additional adalimumab biosimilars are in development, and the FDA continues to review applications. Competition is expected to intensify, which should continue to pressure prices lower over time.

Choose the Best Option for You

The growing Humira biosimilar list gives patients, prescribers, and payers more choices than ever for treating autoimmune conditions with adalimumab. Review your insurance formulary to identify the preferred product, compare concentration and citrate-free options for injection comfort, check manufacturer support programs, and talk with your doctor about switching if cost is a concern — then verify the latest specifics in the FDA Purple Book. For strategies beyond biosimilars, including discount cards, Medicare Extra Help, and patient assistance programs, visit our healthcare costs guide.

Sources

• FDA Purple Book — database of licensed biological products, biosimilars, and interchangeability designations (purplebooksearch.fda.gov)
• U.S. Food and Drug Administration — Biosimilar and Interchangeable Biosimilar Products program (fda.gov/drugs/biosimilars)
• MedlinePlus, U.S. National Library of Medicine — adalimumab drug information and TNF-inhibitor safety (medlineplus.gov)